Cargando…

Modelling the erythroblastic island niche of dyserythropoietic anaemia type IV patients using induced pluripotent stem cells

Introduction: Congenital dyserythropoietic anaemia (CDA) type IV has been associated with an amino acid substitution, Glu325Lys (E325K), in the transcription factor KLF1. These patients present with a range of symptoms, including the persistence of nucleated red blood cells (RBCs) in the peripheral...

Descripción completa

Detalles Bibliográficos
Autores principales: May, Alisha, Ventura, Telma, Fidanza, Antonella, Volmer, Helena, Taylor, Helen, Romanò, Nicola, D’Souza, Sunita L., Bieker, James J., Forrester, Lesley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126837/
https://www.ncbi.nlm.nih.gov/pubmed/37113767
http://dx.doi.org/10.3389/fcell.2023.1148013
_version_ 1785030345307979776
author May, Alisha
Ventura, Telma
Fidanza, Antonella
Volmer, Helena
Taylor, Helen
Romanò, Nicola
D’Souza, Sunita L.
Bieker, James J.
Forrester, Lesley M.
author_facet May, Alisha
Ventura, Telma
Fidanza, Antonella
Volmer, Helena
Taylor, Helen
Romanò, Nicola
D’Souza, Sunita L.
Bieker, James J.
Forrester, Lesley M.
author_sort May, Alisha
collection PubMed
description Introduction: Congenital dyserythropoietic anaemia (CDA) type IV has been associated with an amino acid substitution, Glu325Lys (E325K), in the transcription factor KLF1. These patients present with a range of symptoms, including the persistence of nucleated red blood cells (RBCs) in the peripheral blood which reflects the known role for KLF1 within the erythroid cell lineage. The final stages of RBCs maturation and enucleation take place within the erythroblastic island (EBI) niche in close association with EBI macrophages. It is not known whether the detrimental effects of the E325K mutation in KLF1 are restricted to the erythroid lineage or whether deficiencies in macrophages associated with their niche also contribute to the disease pathology. Methods: To address this question, we generated an in vitro model of the human EBI niche using induced pluripotent stem cells (iPSCs) derived from one CDA type IV patient as well as two iPSC lines genetically modified to express an KLF1-E325K-ER(T2) protein that could be activated with 4OH-tamoxifen. The one patient iPSC line was compared to control lines from two healthy donors and the KLF1-E325K-ER(T2) iPSC line to one inducible KLF1-ER(T2) line generated from the same parental iPSCS. Results: The CDA patient-derived iPSCs and iPSCs expressing the activated KLF1-E325K-ER(T2) protein showed significant deficiencies in the production of erythroid cells with associated disruption of some known KLF1 target genes. Macrophages could be generated from all iPSC lines but when the E325K-ER(T2) fusion protein was activated, we noted the generation of a slightly less mature macrophage population marked by CD93. A subtle trend in their reduced ability to support RBC enucleation was also associated with macrophages carrying the E325K-ER(T2) transgene. Discussion: Taken together these data support the notion that the clinically significant effects of the KLF1-E325K mutation are primarily associated with deficiencies in the erythroid lineage but it is possible that deficiencies in the niche might have the potential to exacerbate the condition. The strategy we describe provides a powerful approach to assess the effects of other mutations in KLF1 as well as other factors associated with the EBI niche.
format Online
Article
Text
id pubmed-10126837
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101268372023-04-26 Modelling the erythroblastic island niche of dyserythropoietic anaemia type IV patients using induced pluripotent stem cells May, Alisha Ventura, Telma Fidanza, Antonella Volmer, Helena Taylor, Helen Romanò, Nicola D’Souza, Sunita L. Bieker, James J. Forrester, Lesley M. Front Cell Dev Biol Cell and Developmental Biology Introduction: Congenital dyserythropoietic anaemia (CDA) type IV has been associated with an amino acid substitution, Glu325Lys (E325K), in the transcription factor KLF1. These patients present with a range of symptoms, including the persistence of nucleated red blood cells (RBCs) in the peripheral blood which reflects the known role for KLF1 within the erythroid cell lineage. The final stages of RBCs maturation and enucleation take place within the erythroblastic island (EBI) niche in close association with EBI macrophages. It is not known whether the detrimental effects of the E325K mutation in KLF1 are restricted to the erythroid lineage or whether deficiencies in macrophages associated with their niche also contribute to the disease pathology. Methods: To address this question, we generated an in vitro model of the human EBI niche using induced pluripotent stem cells (iPSCs) derived from one CDA type IV patient as well as two iPSC lines genetically modified to express an KLF1-E325K-ER(T2) protein that could be activated with 4OH-tamoxifen. The one patient iPSC line was compared to control lines from two healthy donors and the KLF1-E325K-ER(T2) iPSC line to one inducible KLF1-ER(T2) line generated from the same parental iPSCS. Results: The CDA patient-derived iPSCs and iPSCs expressing the activated KLF1-E325K-ER(T2) protein showed significant deficiencies in the production of erythroid cells with associated disruption of some known KLF1 target genes. Macrophages could be generated from all iPSC lines but when the E325K-ER(T2) fusion protein was activated, we noted the generation of a slightly less mature macrophage population marked by CD93. A subtle trend in their reduced ability to support RBC enucleation was also associated with macrophages carrying the E325K-ER(T2) transgene. Discussion: Taken together these data support the notion that the clinically significant effects of the KLF1-E325K mutation are primarily associated with deficiencies in the erythroid lineage but it is possible that deficiencies in the niche might have the potential to exacerbate the condition. The strategy we describe provides a powerful approach to assess the effects of other mutations in KLF1 as well as other factors associated with the EBI niche. Frontiers Media S.A. 2023-04-11 /pmc/articles/PMC10126837/ /pubmed/37113767 http://dx.doi.org/10.3389/fcell.2023.1148013 Text en Copyright © 2023 May, Ventura, Fidanza, Volmer, Taylor, Romanò, D’Souza, Bieker and Forrester. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
May, Alisha
Ventura, Telma
Fidanza, Antonella
Volmer, Helena
Taylor, Helen
Romanò, Nicola
D’Souza, Sunita L.
Bieker, James J.
Forrester, Lesley M.
Modelling the erythroblastic island niche of dyserythropoietic anaemia type IV patients using induced pluripotent stem cells
title Modelling the erythroblastic island niche of dyserythropoietic anaemia type IV patients using induced pluripotent stem cells
title_full Modelling the erythroblastic island niche of dyserythropoietic anaemia type IV patients using induced pluripotent stem cells
title_fullStr Modelling the erythroblastic island niche of dyserythropoietic anaemia type IV patients using induced pluripotent stem cells
title_full_unstemmed Modelling the erythroblastic island niche of dyserythropoietic anaemia type IV patients using induced pluripotent stem cells
title_short Modelling the erythroblastic island niche of dyserythropoietic anaemia type IV patients using induced pluripotent stem cells
title_sort modelling the erythroblastic island niche of dyserythropoietic anaemia type iv patients using induced pluripotent stem cells
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126837/
https://www.ncbi.nlm.nih.gov/pubmed/37113767
http://dx.doi.org/10.3389/fcell.2023.1148013
work_keys_str_mv AT mayalisha modellingtheerythroblasticislandnicheofdyserythropoieticanaemiatypeivpatientsusinginducedpluripotentstemcells
AT venturatelma modellingtheerythroblasticislandnicheofdyserythropoieticanaemiatypeivpatientsusinginducedpluripotentstemcells
AT fidanzaantonella modellingtheerythroblasticislandnicheofdyserythropoieticanaemiatypeivpatientsusinginducedpluripotentstemcells
AT volmerhelena modellingtheerythroblasticislandnicheofdyserythropoieticanaemiatypeivpatientsusinginducedpluripotentstemcells
AT taylorhelen modellingtheerythroblasticislandnicheofdyserythropoieticanaemiatypeivpatientsusinginducedpluripotentstemcells
AT romanonicola modellingtheerythroblasticislandnicheofdyserythropoieticanaemiatypeivpatientsusinginducedpluripotentstemcells
AT dsouzasunital modellingtheerythroblasticislandnicheofdyserythropoieticanaemiatypeivpatientsusinginducedpluripotentstemcells
AT biekerjamesj modellingtheerythroblasticislandnicheofdyserythropoieticanaemiatypeivpatientsusinginducedpluripotentstemcells
AT forresterlesleym modellingtheerythroblasticislandnicheofdyserythropoieticanaemiatypeivpatientsusinginducedpluripotentstemcells